Published in Genet Med on September 01, 2011
Cancer genetic counselor information needs for risk communication: a qualitative evaluation of interview transcripts. J Pers Med (2013) 0.77
Population-based genetic risk prediction and stratification for ovarian cancer: views from women at high risk. Fam Cancer (2015) 0.75
Emotional impact on the results of BRCA1 and BRCA2 genetic test: an observational retrospective study. Hered Cancer Clin Pract (2017) 0.75
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet (2008) 6.22
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology (2004) 2.90
Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ (2012) 2.44
Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol (2005) 2.33
Cost-utility analysis of preoperative radiotherapy in patients with rectal cancer undergoing total mesorectal excision: a study of the Dutch Colorectal Cancer Group. J Clin Oncol (2003) 2.33
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2009) 2.13
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90
Satisfaction with prophylactic mastectomy and breast reconstruction in genetically predisposed women. Plast Reconstr Surg (2006) 1.70
Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study. J Clin Oncol (2003) 1.68
Correcting biases in standard gamble and time tradeoff utilities. Med Decis Making (2004) 1.63
Exploring the reference point in prospect theory: gambles for length of life. Med Decis Making (2006) 1.59
Reliability and validity of the Beck depression inventory in patients with Parkinson's disease. Mov Disord (2006) 1.57
TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet (2010) 1.54
In vivo diagnosis and classification of colorectal neoplasia by chromoendoscopy-guided confocal laser endomicroscopy. Clin Gastroenterol Hepatol (2009) 1.53
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2011) 1.51
Assessment of autonomic dysfunction in Parkinson's disease: the SCOPA-AUT. Mov Disord (2004) 1.48
The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. Cancer Res (2003) 1.44
Intronic variants in BRCA1 and BRCA2 that affect RNA splicing can be reliably selected by splice-site prediction programs. Hum Mutat (2009) 1.41
The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians. Cancer Cell (2011) 1.40
Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases. Breast Cancer Res (2007) 1.40
Developing a policy for paediatric biobanks: principles for good practice. Eur J Hum Genet (2012) 1.39
Genetic risk estimation by healthcare professionals. Med J Aust (2005) 1.39
[Decision-making in preoperative radiotherapy in rectal cancer: variation in provision of information]. Ned Tijdschr Geneeskd (2015) 1.38
Empirical data and moral theory. A plea for integrated empirical ethics. Med Health Care Philos (2004) 1.36
Impact of behavioural problems on spousal caregivers: a comparison between Alzheimer's disease and frontotemporal dementia. Dement Geriatr Cogn Disord (2006) 1.36
Self-reports of health-care utilization: diary or questionnaire? Int J Technol Assess Health Care (2005) 1.35
Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol (2009) 1.33
Postoperative anemia after joint replacement surgery is not related to quality of life during the first two weeks postoperatively. Transfusion (2011) 1.26
How to integrate individual patient values and preferences in clinical practice guidelines? A research protocol. Implement Sci (2010) 1.24
Genetic testing for familial/hereditary breast cancer-comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany. J Community Genet (2011) 1.23
Body weight and risk of breast cancer in BRCA1/2 mutation carriers. Breast Cancer Res Treat (2010) 1.22
A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history. Breast Cancer Res (2009) 1.22
Cost measurement in economic evaluations of health care: whom to ask? Med Care (2004) 1.22
Genetic testing in familial melanoma: uptake and implications. Psychooncology (2008) 1.21
Predictors of sun protection behaviors and severe sunburn in an international online study. Cancer Epidemiol Biomarkers Prev (2010) 1.21
Evaluation of the hospital anxiety and depression scale in patients with Parkinson's disease. Clin Neuropharmacol (2002) 1.15
Clinical characteristics affect the impact of an uninformative DNA test result: the course of worry and distress experienced by women who apply for genetic testing for breast cancer. J Clin Oncol (2006) 1.15
Health state valuations of patients and the general public analytically compared: a meta-analytical comparison of patient and population health state utilities. Value Health (2009) 1.15
How can clinical practice guidelines be adapted to facilitate shared decision making? A qualitative key-informant study. BMJ Qual Saf (2013) 1.14
Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. PLoS Biol (2011) 1.12
The counsellees' view of an unclassified variant in BRCA1/2: recall, interpretation, and impact on life. Psychooncology (2008) 1.12
Cross-sectional study on prevalences of psychiatric disorders in mutation carriers of Huntington's disease compared with mutation-negative first-degree relatives. J Clin Psychiatry (2008) 1.11
Unclassified variants in disease-causing genes: nonuniformity of genetic testing and counselling, a proposal for guidelines. Eur J Hum Genet (2005) 1.10
Comparison of individuals opting for BRCA1/2 or HNPCC genetic susceptibility testing with regard to coping, illness perceptions, illness experiences, family system characteristics and hereditary cancer distress. Patient Educ Couns (2006) 1.10
Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. PLoS One (2013) 1.10
Differences and similarities in breast cancer risk assessment models in clinical practice: which model to choose? Breast Cancer Res Treat (2008) 1.09
Allele-specific regulation of FGFR2 expression is cell type-dependent and may increase breast cancer risk through a paracrine stimulus involving FGF10. Breast Cancer Res (2011) 1.09
Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families. Breast Cancer Res Treat (2010) 1.08
A prospective study of the impact of genetic susceptibility testing for BRCA1/2 or HNPCC on family relationships. Psychooncology (2007) 1.07
A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an example. BMC Cancer (2009) 1.05
Predicting and communicating the risk of recurrence and death in women with early-stage breast cancer: a systematic review of risk prediction models. J Clin Oncol (2013) 1.04
Adverse effects of predictive testing for Huntington disease underestimated: long-term effects 7-10 years after the test. Health Psychol (2004) 1.04
Clinical nature and prognosis of locally recurrent rectal cancer after total mesorectal excision with or without preoperative radiotherapy. J Clin Oncol (2004) 1.04
Importance of clarifying patients' desired role in shared decision making to match their level of engagement with their preferences. BMJ (2013) 1.04
Review of determinants of patients' preferences for adjuvant therapy in cancer. J Clin Oncol (2004) 1.03
The construction of standard gamble utilities. Health Econ (2008) 1.02
Theory-informed design of values clarification methods: a cognitive psychological perspective on patient health-related decision making. Soc Sci Med (2012) 1.02
Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations. J Med Genet (2013) 1.01
A whisper-game perspective on the family communication of DNA-test results: a retrospective study on the communication process of BRCA1/2-test results between proband and relatives. Fam Cancer (2011) 1.01
The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer (2011) 1.01
Genomewide high-density SNP linkage analysis of non-BRCA1/2 breast cancer families identifies various candidate regions and has greater power than microsatellite studies. BMC Genomics (2007) 1.01
Coordinated multidisciplinary care for Huntington's disease. An outpatient department. Brain Res Bull (2009) 1.00
A distinct phenotype characterizes tumors from a putative genetic trait involving chondrosarcoma and breast cancer occurring in the same patient. Lab Invest (2004) 1.00
Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients. Breast Cancer Res Treat (2007) 0.99
Quality in genetic counselling for presymptomatic testing--clinical guidelines for practice across the range of genetic conditions. Eur J Hum Genet (2012) 0.99
Melanoma risk factors, perceived threat and intentional tanning: an international online survey. Eur J Cancer Prev (2010) 0.99
Body image and psychological distress after prophylactic mastectomy and breast reconstruction in genetically predisposed women: a prospective long-term follow-up study. Eur J Cancer (2011) 0.99
Surveillance for hereditary cancer: does the benefit outweigh the psychological burden?--A systematic review. Crit Rev Oncol Hematol (2012) 0.98
Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Hum Mutat (2012) 0.98
Health-related quality of life of children with a positive carrier status for inherited cardiovascular diseases. Am J Med Genet A (2008) 0.98
Effectiveness and cost-effectiveness of meaning-centered group psychotherapy in cancer survivors: protocol of a randomized controlled trial. BMC Psychiatry (2014) 0.97
What's the message? Interpretation of an uninformative BRCA1/2 test result for women at risk of familial breast cancer. Genet Med (2005) 0.96
Predictive genetic testing for cardiovascular diseases: impact on carrier children. Am J Med Genet A (2008) 0.96
Psychological distress in women at increased risk for breast cancer: the role of risk perception. Eur J Cancer (2004) 0.95
Disentangling the Babylonian speech confusion in genetic counseling: an analysis of the reliability and validity of the nomenclature for BRCA1/2 DNA-test results other than pathogenic. Genet Med (2009) 0.95
Prognostic factors for hereditary cancer distress six months after BRCA1/2 or HNPCC genetic susceptibility testing. Eur J Cancer (2006) 0.94
Physical activity and the risk of breast cancer in BRCA1/2 mutation carriers. Breast Cancer Res Treat (2009) 0.94
Rare variants in XRCC2 as breast cancer susceptibility alleles. J Med Genet (2012) 0.94
Feeling at risk: how women interpret their familial breast cancer risk. Am J Med Genet A (2004) 0.93